Drugs Targeting ROS1

  • Rozlytrek (entrectinib) – approved for stage 4 NSCLC patients with a change in ROS1 as detected by a biomarker test.
  • Xalkori (crizotinib) – approved for stage 4 NSCLC patients with a change in ROS1 as detected by a biomarker test.
  • Augtyro (repotrectinib) – approved for adults with locally advanced or metastatic NSCLC with a change in ROS1 as detected by an FDA-approved biomarker test.